Glycobond is a renowned brand that specializes in the field of liver disease and cancer. Established in 2011 as a spin-off from research conducted at Linköping University in Sweden, Glycobond focuses on utilizing recombinant technology to develop carbohydrate-binding peptides for the detection of abnormal glycosylation associated with disease development. Their flagship product, HepaCheC®, is an innovative assay for HCC diagnosis.

Led by a team of seasoned professionals, Glycobond is driven by scientific expertise and a commitment to excellence. The company's first developed recombinant peptide, Mono-F, has garnered worldwide recognition and has received patent protection in various countries. With a distinguished board of directors, including experienced individuals like Stefan Eschbach, Peter Påhlsson, Ingvar Rydén, and Bengt-Harald Jonsson, Glycobond is poised to revolutionize the field of medical biochemistry and glycobiology.

Contact Glycobond today to learn more about their groundbreaking products and services. As a brand at the forefront of scientific advancements, Glycobond is dedicated to improving the diagnosis and treatment of liver disease and cancer